Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy

Laryngoscope

Volumn 118, Issue 9, 2008, Pages 1539-1541

  Burkart, Collin M ^a   Grisel, Jedidiah J ^a,b   Horn, David B ^a  

^a Department of Otolaryngology Head and Neck Surgery   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Antiangiogenic therapy; Bevacizumab; Nasal septal perforation

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; ANAMNESIS; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE INTERVAL; ENDOSCOPY; EPISTAXIS; FEMALE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; LABORATORY TEST; LUNG METASTASIS; METASTASIS; NASAL BIOPSY; NOSE MUCOSA; NOSE SEPTUM PERFORATION; OVARY CANCER; PATIENT REFERRAL; PRIORITY JOURNAL; SYMPTOM; TREATMENT DURATION; VISCERAL METASTASIS; CHEMICALLY INDUCED DISORDER; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; FOLLOW UP; MIDDLE AGED; NOSE DISEASE; NOSE SEPTUM; OVARY TUMOR; PATHOLOGY; RUPTURE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIAGNOSIS, DIFFERENTIAL; ENDOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NASAL SEPTUM; NOSE DISEASES; OVARIAN NEOPLASMS; RUPTURE, SPONTANEOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 51649118405     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLG.0b013e31817c4296     Document Type: Article

References (9)

1. Horn DB, Maisel RH. Angiogenic growth factors: their effects and potential in soft tissue wound healing. Ann Otol Rhinol Laryngol 1992;101:349-354.
2. Heinzerling JH, Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg 2006;63:334-337.
3. Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002;9 (2 suppl) :36-44.
4. Yang JC, Haworth L., Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-434.
5. ® (Bevacizumab) for Intravenous Use [package inset]. South San Francisco, CA: Genentech, Inc., 2004.
6. Fakih MG, Lombardo JC. Bevacizumab-induced nasal septum perforation. The Oncologist 2006;11:85-86.
7. Traina TA, Norton L., Drucker K., Singh B. Nasal Septum Perforation in a Bevacizumab-Treated Patient with Metastatic Breast Cancer. The Oncologist 2006; 11:1070-1071.
8. DeVore RF, Hellerqvist CG, Wakefield GB. Phase I study of the antineovascularization drug CM101. Clin Cancer Res 1997;3:365-372.
9. Shaikh S., Olson JC, Richmond PP. Retinal pigment epithelial tears after bevacizumab injection for exudative age-related macular degeneration. Indian J Ophthalmol 2007;55:470-472.